# A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)

> **NCT04317599** · — · COMPLETED · sponsor: **Pierre Fabre Medicament** · enrollment: 274 (actual)

## Conditions studied

- BRAF V600E Mutation Positive
- Metastatic Colorectal Cancer

## Interventions

- **OTHER:** Non interventional

## Key facts

- **NCT ID:** NCT04317599
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-12
- **Primary completion:** 2021-03-04
- **Final completion:** 2021-05-12
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2026-01-02

## Collaborators

- Clinact

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04317599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04317599, "A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04317599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*